Please assess the completion status of the following clinical trial:

Trial Title: A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed written informed consent prior to study entry~2. Patients with recurrent ESCC after radiotherapy, confirmed by imaging and pathology or cytology;~3. Capable for chemo-radiotherapy;~4. The existence of measurable lesions;~5. ECOG PS of 0 or 1~6. Possible semi-liquid diet;~7. Expected lifetime≥3 months~8. normal bone marrow reserve: ANC count ≥1500/mm3;platelet count ≥100,000/ mm3,hemoglobin≥9g/dl~9. normal hepatic function:bilirubin level ≤1.5×ULN;AST/ALT≤1.5×ULN~10. normal renal function: serum creatinine≤1.5mg/dl and calculated creatinine clearance ≥60ml/min~11. Normal cardiac function~12. Subjects tumor tissue available for the relevant biomarker detection~13. Clinical stage: No distant metastasis~Exclusion Criteria:~1. Female subject who is during pregnancy or lactation, and the subject who have fertility don't take effective contraception during study~2. Any mental illness or nervous system lesions or can't tell treatment response clearly (such as cerebrovascular accident sequelae)~3. Any serious uncontrolled disease and infection, such as severe heart, liver, kidney diseases or diabetes, can't complete the treatment plan~4. Patients who have other malignant lesions, except curable skin cancer (non-melanoma skin cancer),carcinoma in situ of cervix or serve disease cured for 5 years~5. Patients with distant metastasis.~6. Patients who have obvious esophageal ulcers or have above moderate pains in chest-back or have symptoms of esophageal perforation~7. received anti-cancer treatment of esophageal cancer before the group, including surgery, radiotherapy, chemotherapy (induction of chemotherapy before the group is greater than or equal to two cycles)~8. Not esophageal squamous carcinoma confirmed by pathology or cytology~9. History of active hepatitis~10. Unable to comprehend the study requirement or who are not likely to comply with the study requirements~11. Significant disease which, in the investigator's opinion, would exclude the patient from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Glycididazole (Type: EXPERIMENTAL): Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 \~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T\>40Gy/20f,week 1-\>5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues